Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenji Omae

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
International Journal of Clinical Oncology|February 12, 2024
First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world dataHiroki Ishihara, Kenji Omae, Yuki Nemoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 22, 2022
[Management of Chronic Kidney Disease in Cancer Survivors]Chihiro Kondoh, Kenji Ishikura, Satoko Ichioka, et al.
BMC Pulmonary Medicine|August 28, 2023
Development and external validation of the DOAT and DOATS scores: simple decision support tools to identify disease progression among nonelderly patients with mild/moderate COVID-19Yoko Shibata, Kenji Omae, Hiroyuki Minemura, et al.
Annals of Internal Medicine|October 17, 2022
The Impact of the COVID-19 Pandemic and Associated Control Measures on the Mental Health of the General Population : A Systematic Review and Dose-Response Meta-analysisGeorgia Salanti, Natalie Peter, Thomy Tonia, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
International Journal of Clinical Oncology|February 12, 2024
First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world dataHiroki Ishihara, Kenji Omae, Yuki Nemoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 22, 2022
[Management of Chronic Kidney Disease in Cancer Survivors]Chihiro Kondoh, Kenji Ishikura, Satoko Ichioka, et al.
BMC Pulmonary Medicine|August 28, 2023
Development and external validation of the DOAT and DOATS scores: simple decision support tools to identify disease progression among nonelderly patients with mild/moderate COVID-19Yoko Shibata, Kenji Omae, Hiroyuki Minemura, et al.
Annals of Internal Medicine|October 17, 2022
The Impact of the COVID-19 Pandemic and Associated Control Measures on the Mental Health of the General Population : A Systematic Review and Dose-Response Meta-analysisGeorgia Salanti, Natalie Peter, Thomy Tonia, et al.
Pageof 11